Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best long term low volatility stocks to buy now. On July 16, Thermo Fisher Scientific Inc.

Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

With an aim to enable additional U.S. drug product manufacturing, Thermo Fisher Scientific and Sanofi have decided to expand their strategic partnership. Under the terms of the agreement, Thermo ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in adults and adolescents with moderate-to-severe ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients ...